



## **IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational Gen-C study.**

Mangia, A; De Ledinghen, V; Bailly, F; Brahm, J; Keiss, J; Valantinas, J; Rasmann, N; Messinger, D; Tatsch, F; Bakalos, G; Foster, GR; Gen-C study group,

© 2016 The Author(s)

CC-BY

For additional information about this publication click this link.

<http://qmro.qmul.ac.uk/xmlui/handle/123456789/18367>

Information about this research object was correct at the time of download; we occasionally make corrections to records, please therefore check the published record when citing. For more information contact [scholarlycommunications@qmul.ac.uk](mailto:scholarlycommunications@qmul.ac.uk)

RESEARCH

Open Access



# *IL28B* genotype is associated with cirrhosis or transition to cirrhosis in treatment-naïve patients with chronic HCV genotype 1 infection: the international observational Gen-C study

Alessandra Mangia<sup>1\*</sup>, Victor De Ledinghen<sup>2</sup>, François Bailly<sup>3</sup>, Javier Brahm<sup>4</sup>, Jazeps Keiss<sup>5</sup>, Jonas Valantinas<sup>6</sup>, Nele Rasmann<sup>7</sup>, Diethelm Messinger<sup>8</sup>, Fernando Tatsch<sup>9,10</sup>, Georgios Bakalos<sup>11</sup>, Graham R. Foster<sup>12</sup> and on behalf of the Gen-C study group

## Abstract

**Background and purpose:** Contradictory data exist on the association between host interleukin-28B (*IL28B*) rs12979860 genotype and liver fibrosis in patients with chronic hepatitis C (CHC). This large, international, observational study (NCT01675427/MV25600) investigated relationships between *IL28B* rs12979860 genotype and liver fibrosis stage in CHC patients.

**Methods:** A total of 3003 adult, treatment-naïve CHC patients were enrolled into the study. Patients made one study visit to provide a blood sample for genotyping; other data were obtained from medical records.

**Results:** 2916 patients comprised the analysis population; the majority were enrolled in Europe ( $n = 2119$ ), were Caucasian ( $n = 2582$ ) and had hepatitis C virus (HCV) genotype (G)1 infection ( $n = 1702$ ) (G2 = 323, G3 = 574, G4 = 260). Distribution of *IL28B* genotypes varied according to region of enrolment, patient ethnicity and HCV genotype. A significant association was observed between increasing number of *IL28B* T alleles and the prevalence of cirrhosis/transition to cirrhosis (based on biopsy or non-invasive assessments) in G1-infected patients (CC = 22.2% [111/499], CT = 27.5% [255/928], TT = 32.3% [87/269];  $p = 0.0018$ ). The association was significant in the large subgroup of European Caucasian G1 patients ( $n = 1245$ ) but not in the smaller Asian ( $n = 25$ ), Latin American ( $n = 137$ ) or Middle Eastern ( $n = 289$ ) G1 subgroups. *IL28B* genotype was not associated with liver fibrosis stage in patients with HCV G2, G3 or G4 infection.

**Conclusion:** This large, international study found that *IL28B* rs12979860 genotype is significantly associated with liver fibrosis stage in CHC patients with HCV G1 infection. This association was evident in European Caucasians but not in G1-infected patients from Asia, Latin America or the Middle East.

**Keywords:** Hepatitis C, Gen-C study, *IL28B*, Advanced fibrosis, Chronic hepatitis C

\*Correspondence: a.mangia@tin.it

<sup>1</sup> Liver Unit, IRCCS Hospital 'Casa Sollievo della Sofferenza', San Giovanni Rotondo 71013, Italy

Full list of author information is available at the end of the article

## Background

Host interleukin-28B (*IL28B*) genotype is associated with spontaneous clearance of acute hepatitis C virus (HCV) infection, response to interferon (IFN)-based treatment, and with the development of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C (CHC) (Thomas et al. 2009; Ge et al. 2009; Zhang et al. 2016). Genome-wide association studies have identified single-nucleotide polymorphisms (SNPs) in close proximity to the *IL28B* gene that encode for IFN lambda (IFN- $\lambda$ ), with strong associations with spontaneous or IFN-induced clearance of HCV (Thomas et al. 2009; Ge et al. 2009; Rauch et al. 2010; Suppiah et al. 2009; Tanaka et al. 2009). In particular, a host *IL28B* rs12979860 CC genotype is associated with the highest, and TT genotype the lowest, rates of response to IFN-based therapy (Thomas et al. 2009; Ge et al. 2009; Mangia et al. 2010; Asselah et al. 2012; De Nicola et al. 2012; Poordad et al. 2012; Lawitz et al. 2013; Susser et al. 2014). The T allele also increases the risk of HCC associated with HCV (Zhang et al. 2016). In addition, differences in the distribution of *IL28B* genotypes explain, in part, historical observations of low sustained virological response (SVR) rates in Black or Latino patients and high SVR rates in Asian patients (Muir et al. 2004; Yu et al. 2008; Rodriguez-Torres et al. 2009).

Despite the established role of host *IL28B* genotype as a predictor of response to therapy, the association between *IL28B* polymorphisms and the natural history of HCV is currently the subject of debate. CHC patients with an *IL28B* CC genotype had higher alanine transaminase (ALT) levels and greater hepatic necro-inflammatory activity at baseline, with worse clinical outcomes over 4 years of follow-up than patients with non-CC genotypes (Noureddin et al. 2013). However, the same study observed no difference in the rate of fibrosis progression between patients with CC and non-CC genotypes. Other studies have yielded contradictory results on the association between *IL28B* genotype and fibrosis progression (Asselah et al. 2012; Falletti et al. 2011; Fabris et al. 2011; Marabita et al. 2011; Di Marco et al. 2012; D'Ambrosio et al. 2014).

While the efficacy of recently introduced, IFN-free treatment regimens is not affected by host *IL28B* genotype, their use is limited to patients with advanced fibrosis in many jurisdictions (Lawitz et al. 2013; Jacobson et al. 2013). Therefore, predictors of fibrosis progression may provide a valuable tool for selection of patients eligible for treatment. In addition, dual peginterferon alpha/ribavirin therapy and protease inhibitor-based triple therapy continue to be used in many regions (Pawlotsky 2014). Given that advanced fibrosis is associated with lower rates of SVR to IFN-based therapies, the identification factors predictive of fibrosis stage has implications

for treatment selection and optimization (Poordad et al. 2012; Lawitz et al. 2013; Hadziyannis et al. 2004; Bonnet et al. 2014; Manns et al. 2014; Jacobson et al. 2014).

The primary objective of the Gen-C study was to investigate associations between *IL28B* genotype and fibrosis stage in CHC patients, in addition to gathering further information on the distribution of *IL28B* genotypes by HCV genotype, geographic region and ethnicity. The final results from treatment-naive patients are reported here.

## Methods

### Patients and study design

Gen-C is a large, international, observational study of adults with CHC (clinicaltrials.gov, trial identifier NCT01675427). Patients were excluded if they had hepatitis B virus co-infection, a history of decompensated liver disease, major organ transplantation or end-stage renal disease. Only treatment-naive patients were included in the present analysis. Enrolment was at the discretion of the investigator.

The primary objective of the Gen-C study was to investigate the relationship between *IL28B* genotypes and liver fibrosis stage in patients with CHC.

Secondary objectives included relationships between *IL28B* genotypes and liver inflammation, ALT levels and patient demographics, and the distribution of *IL28B* genotypes by HCV genotype, geographic region and ethnicity.

### Data collection

Patients who provided written, informed consent made one study visit for blood sample collection, which was analysed in a central laboratory in Germany or Italy.

A 5 ml sample of whole blood was collected in a tube containing ethylenediaminetetraacetic acid. After collection, the tube was gently inverted 10 times and was not to be centrifuged. A bar-coded label was then applied to the tube and the sample was stored at  $-20^{\circ}\text{C}$  before being packed in dry ice and shipped by courier to the central laboratory. Samples were stored at  $-20^{\circ}\text{C}$  until DNA extraction then were thawed overnight (i.e., for approximately 16 h) and rolled for approximately 30 min before opening.

Standard polymerase chain reaction technology was used to genotype SNPs near *IL28B* (rs12979860 [CC, TC and TT] and rs8099917 [TT, GT or GG]) and inosine triphosphate pyrophosphatase (*ITPA*) (rs1127354 [AA, CA or CC] and rs7270101 [CC, AC or AA]). Positive controls for *IL28B* rs12979860 TC and rs8099917 TG were obtained from TIB MOLBIOL GmbH, Berlin, Germany. Nucleic acid purification was performed using the MagNa Pure 96 System (Roche Diagnostics, Mannheim,

Germany). Genomic DNA was extracted from a 50  $\mu$ L sample by adding MagNa Pure96 to make up an eluate of 100  $\mu$ L. Genotype was then determined by commercial genotyping assays (LightMix Kit rs12979860 IL28B, LightSNiP rs8099917 IL28B, LightSNiP rs7270101 ITPA, LightSNiP rs1127354 ITPA; Roche Diagnostics, GmbH) using an eluate of 5  $\mu$ L.

The results of previous invasive or non-invasive fibrosis assessments were entered in the electronic Case Report Form. Investigators recorded the date, type (invasive or non-invasive) and result of the assessment. Fibrosis stage was documented categorically (Cirrhosis, Transition to cirrhosis, Advanced fibrosis-non-cirrhotic, Mild/minimal fibrosis, No fibrosis). Cirrhosis/transition to cirrhosis was defined by biopsy (Ishak 4–6, METAVIR 3–4, Batts and Ludwig 3–4, Knodell 3–4 or Scheuer 3–4) or non-invasive assessment.

### Statistical analyses

Enrolment of 1500 treatment-naive and 1500 treatment-experienced patients with evaluable data was estimated to provide 80% power for a Chi square test to detect an association between liver fibrosis stage (five degrees of freedom) and *IL28B* genotype (three degrees of freedom) at a significance level of 0.05. The final enrolment target of 4000–6000 patients was arrived at after allowing for patient dropout and patients without evaluable data.

The analysis population was defined as all patients with blood samples and available data for *IL28B* SNPs. For analysis of the primary endpoint, patients were categorized as having cirrhosis/transition to cirrhosis or no cirrhosis. The relationship between cirrhosis status (cirrhosis/transition to cirrhosis vs no cirrhosis) and number of rs12979860 *IL28B* T alleles was investigated by Cochran-Armitage trend test. The relationship between *IL28B* genotype and all other fibrosis measurements (e.g. METAVIR fibrosis stage) was investigated using the Jonckheere-Terpstra trend test. The same methods were used to investigate the relationship between *IL28B* and other continuous, ordinal or binary variables, while the Pearson Chi square test was used to compare the association between *IL28B* genotypes and nominal variables.

Relationships between baseline characteristics and cirrhosis status were explored by multivariate logistic regression (MLR) analysis. Variables considered in the analysis were: alcohol consumption, ALT ratio, aspartate transaminase (AST) ratio, age, autoimmune disease, body mass index (BMI), body weight, ethnic origin, glucose intolerance/diabetes, HCV genotype, HCV RNA level, HIV–HCV co-infection, liver disease other than CHC, platelets, region of enrolment and years since HCV infection.

## Results

A total of 3003 treatment-naive patients were enrolled at 213 centres across 30 countries between August 2011 (first patient) and September 2013 (last patient last visit) (Fig. 1). Overall, 87 patients were excluded, and therefore the analysis population comprised 2916 patients.

Among the total population of 2916 patients, a fibrosis assessment was conducted in 2902 individuals (99.5%), of whom 26.1% were diagnosed with cirrhosis/transition to cirrhosis (Table 1). The majority of patients were male, Caucasian and had HCV G1 infection, with similar characteristics across *IL28B* rs12979860 genotypes (Table 1). More patients with CC or CT compared with TT genotypes had a high viral load and elevated ALT levels. The distribution of HCV genotypes varied by region (Fig. 2).

### *IL28B* genotype and liver fibrosis stage

Among HCV G1-infected patients, the prevalence of cirrhosis/transition to cirrhosis increased with the number of rs12979860 T alleles overall ( $p = 0.0018$ ) (Fig. 3a), in Caucasians ( $p = 0.0010$ ) (Fig. 3b) and in European Caucasians ( $p = 0.0023$ ) (Fig. 3c).


No statistically significant associations were observed for other HCV genotypes. Among HCV G1 patients enrolled at European study sites ( $n = 1245$ ), an association was observed between the prevalence of cirrhosis/transition to cirrhosis and the number of rs12979860 T alleles ( $p = 0.0030$ , Table 2). For patients enrolled in Asia, Latin America or the Middle East, no significant associations were observed (Table 2; Additional file 1: Tables S1–S4). However, these results should be interpreted with caution due to low patient numbers.

### MLR analyses

Older age, higher BMI, HCV G1 infection (vs G2), higher AST ratio, lower platelet count, enrolment at an Asian/Middle Eastern site (vs European), liver disease other than CHC and glucose intolerance/diabetes were significantly associated with an increased risk of cirrhosis/transition to cirrhosis (Fig. 4a). *IL28B* genotype was not associated with cirrhosis/transition to cirrhosis in the final MLR model. In contrast, when only HCV G1-infected patients were considered, rs12979860 genotype (CT or TT vs CC) was significantly associated with cirrhosis/transition to cirrhosis (Fig. 4b). When the analysis was further restricted to European HCV G1 patients, rs8099917 GG and TG genotype (vs TT) was significantly associated with cirrhosis/transition to cirrhosis (Fig. 4c).

### *IL28B* rs12979860 genotype, serum ALT levels and necro-inflammatory grade

A statistically significant decrease in mean ALT ratio was observed with an increasing number of rs12979860



T alleles for G1 ( $p = 0.0007$ ), G2 ( $p = 0.0061$ ) and G3 ( $p < 0.0001$ ) but not G4 patients (Additional file 1: Table S5).

No association was observed between *IL28B* genotype and METAVIR fibrosis stage or necro-inflammatory grade (Additional file 1: Tables S6 and S7), or liver stiffness (Additional file 1: Table S8) overall or when stratified by HCV genotype. There was however significant association between *IL28B* genotype and AST to platelet ratio index (APRI) score and Fibrosis-4 (FIB-4) score (age, AST, platelet count and ALT) in the overall population and in the subgroup of patients with G2 and G3 infection (Additional file 1: Tables S9 and S10).

#### rs12979860 genotype distributions

In general, an rs12979860 CT genotype was more common than a CC or TT genotype (Fig. 5a) and there was a significant association between HCV genotype and *IL28B* genotype ( $p < 0.0001$ ), with the CC genotype occurring more frequently in G2 and G3 patients than in G1 and G4 patients.

rs12979860 genotype was significantly associated with region of enrolment overall ( $p < 0.0001$ , Fig. 5b) and in HCV G1 and G4 patients [ $p < 0.0001$  and  $p = 0.0467$ , respectively (Table 3)]. rs12979860 distribution was not, however, homogenous across the countries within each region (Additional file 1: Table S8).

rs12979860 genotype was significantly associated with patient ethnic origin ( $p < 0.0001$ ); CC was the most common genotype in Asian patients, but was infrequent in Black patients (Fig. 5c).

#### Discussion

The primary finding of the Gen-C study was a positive association between an increasing number of rs12979860 T alleles and the prevalence of cirrhosis/transition to cirrhosis in treatment-naïve G1 patients. While the positive association between T allele and fibrosis stage observed for HCV G1 broadly supports findings from several previous studies, it should be taken into account that these studies did not differentiate between HCV genotypes,

**Table 1 Patient demographics and background disease characteristics**

	<i>IL28B</i> rs12979860 genotype			P value <sup>e</sup>
	CC (n = 978)	CT (n = 1518)	TT (n = 420)	
Mean age, years ± SD	46.8 ± 13.6	47.3 ± 13.2	46.8 ± 12.6	0.6973 <sup>e</sup>
G1 (n = 1702)	47.9 ± 13.3	48.5 ± 13.2	48.1 ± 12.2	0.6602 <sup>e</sup>
G2 (n = 323)	54.7 ± 13.1	55.1 ± 12.6	51.1 ± 15.9	0.5182 <sup>e</sup>
G3 (n = 574)	39.2 ± 9.8	39.6 ± 10.3	39.0 ± 9.4	0.6864 <sup>e</sup>
G4 (n = 260)	45.5 ± 13.2	44.3 ± 10.2	46.0 ± 10.4	0.7789 <sup>e</sup>
Male, n (%)	582 (59.5)	802 (52.8)	224 (53.3)	0.0049 <sup>f</sup>
Ethnic origin, n (%)				<0.0001 <sup>g</sup>
Asian	89 (9.1)	83 (5.5)	9 (2.1)	
Black	5 (0.5)	24 (1.6)	19 (4.5)	
Caucasian	860 (87.9)	1349 (88.9)	373 (88.8)	
Other <sup>a</sup>	24 (2.5)	62 (4.1)	19 (4.5)	
Region, n (%)				<0.0001 <sup>g</sup>
Asia	78 (8.0)	66 (4.3)	8 (1.9)	
Europe	721 (73.7)	1095 (72.1)	303 (72.1)	
Middle East	138 (14.1)	272 (17.9)	75 (17.9)	
Latin America	41 (4.2)	85 (5.6)	34 (8.1)	
BMI, kg/m <sup>2</sup> , mean ± SD	25.8 ± 4.4	26.0 ± 4.5	26.0 ± 4.7	0.2617 <sup>e</sup>
HCV genotype, n (%)				<0.0001 <sup>g</sup>
Known genotype	957 (97.9)	1501 (98.9)	414 (98.6)	
G1 <sup>b</sup>	500 (52.2)	930 (62.0)	272 (65.7)	
G2 <sup>b</sup>	126 (13.2)	160 (10.7)	37 (8.9)	
G3 <sup>b</sup>	232 (24.2)	277 (18.5)	65 (15.7)	
G4 <sup>b</sup>	92 (9.6)	129 (8.6)	39 (9.4)	
G5/6 <sup>b</sup>	7 (0.7)	5 (0.3)	1 (0.2)	
Unknown/missing	21 (2.1)	17 (1.1)	6 (1.4)	
Duration of HCV infection, mean years ± SD	14.0 ± 12.3	14.0 ± 12.6	13.0 ± 12.4	0.1860 <sup>e</sup>
G1 (n = 1615)	14.8 ± 13.1	14.5 ± 13.0	12.7 ± 12.5	0.0536 <sup>e</sup>
G2 (n = 303)	16.6 ± 12.9	15.9 ± 13.5	16.6 ± 15.8	0.5129 <sup>e</sup>
G3 (n = 552)	10.9 ± 9.6	11.8 ± 10.7	11.3 ± 8.5	0.4443 <sup>e</sup>
G4 (n = 249)	13.7 ± 10.6	13.1 ± 10.4	14.8 ± 13.8	0.9733 <sup>e</sup>
HIV–HCV co-infection, n (%)	38 (3.9)	49 (3.2)	15 (3.6)	0.6000 <sup>f</sup>
Autoimmune disease, n (%)	23 (2.4)	46 (3.0)	6 (1.4)	0.6433 <sup>f</sup>
Liver disease other than CHC, n (%)	34 (3.5)	35 (2.3)	13 (3.1)	0.3728 <sup>f</sup>
Glucose intolerance/diabetes, n (%)	73 (7.5)	125 (8.2)	33 (7.9)	0.6614 <sup>f</sup>
Alcohol consumption, mean units/week ± SD	1.83 ± 8.7	1.10 ± 5.2	0.87 ± 3.5	0.1423 <sup>e</sup>
Previous/current drug use/methadone or substitute therapy, n (%)	289 (29.6)	361 (23.8)	96 (22.9)	0.0013 <sup>f</sup>
Smoking, n (%) <sup>b</sup>				0.0070 <sup>g</sup>
Never	496 (50.9)	887 (58.5)	230 (54.9)	
Previous	141 (14.5)	192 (12.7)	56 (13.4)	
Current	338 (34.7)	438 (28.9)	133 (31.7)	
ITPA rs1127354, CC, n (%)	818 (83.6)	1338 (88.1)	372 (88.6)	0.0020 <sup>f</sup>
ITPA rs7270101, AA, n (%)	793 (81.1)	1254 (82.6)	342 (81.4)	0.6563 <sup>f</sup>
Mean ALT, IU/L ± SD	104.1 ± 103.5	83.4 ± 79.2	72.9 ± 63.8	<0.0001 <sup>e</sup>
Mean ALT ratio ± SD <sup>c</sup>	2.28 ± 2.07	1.88 ± 1.55	1.65 ± 1.31	<0.0001 <sup>e</sup>
G1 (n = 1671)	2.09 ± 1.94	1.77 ± 1.38	1.63 ± 1.30	0.0007 <sup>e</sup>
G2 (n = 312)	2.42 ± 2.58	1.96 ± 1.96	1.21 ± 0.829	0.0061 <sup>e</sup>
G3 (n = 565)	2.80 ± 2.15	2.32 ± 1.91	2.05 ± 1.62	<0.0001 <sup>e</sup>
G4 (n = 247)	2.00 ± 1.75	1.66 ± 1.11	1.65 ± 1.09	0.3885 <sup>e</sup>

**Table 1 continued**

	<i>IL28B</i> rs12979860 genotype			P value <sup>e</sup>
	CC (n = 978)	CT (n = 1518)	TT (n = 420)	
Mean HCV RNA, log <sub>10</sub> IU/mL ± SD	5.94 ± 0.99	5.83 ± 0.81	5.68 ± 0.83	<0.0001 <sup>e</sup>
HCV RNA > 800,000 IU/mL, n (%) <sup>bd</sup>	607/959 (63.3)	764/1498 (51.0)	179/416 (43.0)	<0.0001 <sup>f</sup>
G1	320/495 (64.6)	493/921 (53.5)	116/268 (43.3)	<0.0001 <sup>f</sup>
G2	81/124 (65.3)	80/157 (51.0)	23/37 (62.2)	0.1853
G3	152/231 (65.8)	131/276 (47.5)	22/65 (33.8)	<0.0001
G4	44/92 (47.8)	53/128 (41.4)	14/39 (35.9)	0.1792
Assessment of cirrhosis, n (%)				0.0723 <sup>g</sup>
Biopsy	295 (30.2)	419 (27.6)	114 (27.1)	
Noninvasive	646 (66.0)	1046 (68.9)	289 (68.8)	
Both	37 (3.8)	46 (3.0)	12 (2.9)	
None	1 (0.1)	7 (0.5)	5 (1.2)	
Fibrosis stage (biopsy or noninvasive), n (%)				
Assessment made	976 (99.8)	1511 (99.5)	415 (98.8)	
Cirrhosis/transition to cirrhosis <sup>b</sup>	248 (25.4)	390 (25.8)	119 (28.7)	0.2702 <sup>f</sup>
No cirrhosis <sup>b</sup>	728 (74.6)	1121 (74.2)	296 (71.3)	
Missing	2 (0.2)	7 (0.5)	5 (1.2)	

ALT alanine transaminase, *IL28B* interleukin-28B, *ITPA* inosine triphosphate pyrophosphatase

<sup>a</sup> Ethnic origin was selected from a drop-down menu in the CSR; "Other" may include patients who are Hispanic, Latino, or identified themselves as Mixed Race

<sup>b</sup> Percentages calculated for patients with available data only


<sup>c</sup> ALT ratio is ALT divided by upper limit of normal range


<sup>d</sup> Includes HCV RNA categories reported as ≤800,000 or >800,000 IU/mL

<sup>e</sup> Jonckheere-Terpstra Test for a trend of a continuous variable across the three *IL28B* genotype categories

<sup>f</sup> Cochran-Armitage Trend Test for a trend in binomial proportions across the three *IL28B* genotype categories

<sup>g</sup> Pearson Chi square test





**Fig. 3** The association between *IL28B* rs12979860 genotype and liver fibrosis by HCV genotype overall (a), in Caucasian patients with HCV G1 infection (b), and in European Caucasian patients with HCV G1 infection (c). Significant associations were found between *IL28B* rs12979860 genotype and liver fibrosis in patients with HCV G1 infection ( $p = 0.0018$ ) (a), in Caucasian treatment-naïve patients with HCV G1 infection ( $p = 0.0010$ ) (b), and in treatment-naïve European Caucasian patients with HCV G1 infection ( $p = 0.0023$ ) (c). <sup>a</sup>Cochran-Armitage Trend Test for a trend in binomial proportions across the three *IL28B* genotypes

and also included relatively small numbers of patients (Falleti et al. 2011; Fabris et al. 2011; Di Marco et al. 2012).

There is also evidence that contradicts the results of the present study: analyses in G1 patients have reported that a CC genotype is associated with a higher prevalence



**Table 2 Association between liver fibrosis and *IL28B* rs12979860 genotype in patients with HCV G1 infection, by region of enrolment**

Patients, n (%)	<i>IL28B</i> rs12979860 genotype			p value <sup>a</sup>
	CC	TC	TT	
Asia (n = 25)				
Cirrhosis/transition to cirrhosis	8 (50.0)	5 (55.6)	ND	
No cirrhosis	8 (50.0)	4 (52.3)	ND	0.7896
European (n = 1245)				
Cirrhosis/transition to cirrhosis	78 (20.2)	168 (24.8)	57 (31.7)	
No cirrhosis	309 (79.8)	510 (75.2)	123 (68.3)	0.0030
Latin America (n = 137)				
Cirrhosis/transition to cirrhosis	9 (29.0)	25 (33.8)	10 (31.3)	
No cirrhosis	22 (71.0)	49 (66.2)	22 (68.8)	0.8547
Middle East (n = 289)				
Cirrhosis/transition to cirrhosis	16 (24.6)	57 (34.1)	20 (35.1)	
No cirrhosis	49 (75.4)	110 (65.9)	37 (64.9)	0.2022

ND no data available

<sup>a</sup> Cochran-Armitage trend test for a trend in binomial proportions across the three *IL28B* genotype categories


of cirrhosis/transition to cirrhosis (Abe et al. 2010), and that there is no relationship between *IL28B* and fibrosis stage (D'Ambrosio et al. 2014; Bochud et al. 2012). The studies by D'Ambrosio et al. and Abe et al. measured fibrosis by biopsy; however, they included relatively small numbers of patients (D'Ambrosio et al. 2014; Abe et al. 2010). While the study by Bochud et al. (2012) included a similar number (n = 919) of Caucasian G1-infected, treatment-naïve patients, the median duration of HCV infection was longer (21 vs ~14 years), and more patients had HIV–HCV co-infection (5 vs 3.5%). Two further studies found no association between rs12979860 genotype and fibrosis stage (Noureddin et al. 2013; Marabita et al. 2011).

Associations between *IL28B* genotype and liver fibrosis were restricted to HCV G1 infection in the present study. When the data were analysed by geographic region, the association between *IL28B* genotype and fibrosis status remained statistically significant in the large subgroup of European Caucasian patients with G1 infection but was not statistically significant in other populations. The lack of a relationship in the smaller subgroup of Asian, Latin American and Middle Eastern patients with G1 infection may simply be due to the smaller sample size, or may be due to factors related to ethnicity that were not measured in this analysis. Interestingly there was also a significant


association between *IL28B* genotype and APRI score and FIB-4 score in the overall population and in patients with G2 and G3 infection, but not in those with G1 infection. Strong conclusions cannot be drawn regarding the overall association between *IL28B* genotype and fibrosis status, as significant associations between C allele frequency and cirrhosis/transition to cirrhosis have been reported previously (Bochud et al. 2012; Rembeck et al. 2012).

The primary immune response to HCV infection is mediated predominantly through IFN- $\lambda$  cytokines and may be influenced by *IL28B* genotype (Thomas et al. 2012; Watanabe et al. 2013). Patients with a “favourable” rs12979860 CC genotype are more likely to experience spontaneous viral clearance and respond to IFN-based therapy (Thomas et al. 2009; Ge et al. 2009), while those with the T allele may be at increased risk of HCV-related HCC (Zhang et al. 2016). Interestingly, there is a well-established association between this “favourable” genotype for viral clearance (CC), and increased markers of intra-hepatic inflammatory response to HCV infection (Noureddin et al. 2013; D'Ambrosio et al. 2014; Abe et al. 2010; Bochud et al. 2012; Rembeck et al. 2012). The presence of significantly higher necro-inflammatory activity and serum ALT levels in patients with CC genotypes has been interpreted as an indication of an enhanced immune response in patients with CC genotypes as compared with non-CC genotypes (Noureddin et al. 2013; D'Ambrosio et al. 2014; Rembeck et al. 2012). A more vigorous immune response would be expected to lead to more rapid fibrosis progression over time in patients who do not experience spontaneous viral clearance. However, an association with liver fibrosis stage and *IL28B* genotype is less well established (Noureddin et al. 2013; D'Ambrosio et al. 2014; Abe et al. 2010; Bochud et al. 2012; Rembeck et al. 2012). In the current study, the CC genotype was associated with higher ALT ratios and a lower prevalence of cirrhosis/transition to cirrhosis in patients with HCV G1 infection. These results support the interpretation that the “favourable” CC genotype is associated with a more vigorous antiviral immune response but not with higher incidence of fibrosis. Unfortunately, inflammatory grade was not available for many patients, which limits the strength of this conclusion.

Recently, it has been shown that different combinations of *IL28B* genotype and toll-like receptor-2 (TLR-2) variants are associated with different manifestations of HCV-related liver disease and lymphoproliferative diseases (De Re et al. 2016). The *IL28B* CC genotype exerts a protective effect on CHC and the development of cirrhosis and HCC, while the TLR-2 *del/del* genotype was associated with an increased risk of HCC. In combination, the presence of one or more TLR-2 *del* alleles abolished the



**Fig. 4** Multiple logistic regression analysis for cirrhosis or transition to cirrhosis in all patients (**a**), all patients with HCV G1 infection (**b**), and all European Caucasian patients with HCV G1 infection (**c**). *AST* aspartate transaminase; *MLR* multiple logistic regression



**Table 3** Distribution of *IL28B* rs12979860 genotype by region of enrolment and HCV RNA genotype

HCV genotype	<i>IL28B</i> rs12979860 genotype			p value <sup>a</sup>
	CC	CT	TT	
G1 (n = 1702)				
Asia (n = 25)	16 (64.0)	9 (36.0)	0 (0.0)	
Europe (n = 1251)	388 (31.0)	680 (54.4)	183 (14.6)	
Middle East (n = 289)	65 (22.5)	167 (57.8)	57 (19.7)	
Latin America (n = 137)	31 (22.6)	74 (54.0)	32 (23.4)	
Total (n = 1702)	500 (29.4)	930 (54.6)	272 (16.0)	<0.0001
G2 (n = 323)				
Asia (n = 6)	4 (66.7)	2 (33.3)	0 (0.0)	
Europe (n = 291)	111 (38.1)	144 (49.5)	36 (12.4)	
Middle East (n = 19)	7 (36.8)	12 (63.2)	0 (0.0)	
Latin America (n = 7)	4 (57.1)	2 (28.6)	1 (14.3)	
Total (n = 323)	126 (39.0)	160 (49.5)	37 (11.5)	0.3572
G3 (n = 574)				
Asia (n = 105)	45 (42.9)	52 (49.5)	8 (7.6)	
Europe (n = 432)	177 (41.0)	200 (46.3)	55 (12.7)	
Middle East (n = 30)	8 (26.7)	20 (66.7)	2 (6.7)	
Latin America (n = 7)	2 (28.6)	5 (71.4)	0 (0.0)	
Total (n = 574)	232 (40.4)	277 (48.3)	65 (11.3)	0.2041
G4 (n = 260)				
Asia (n = 0)	0	0	0	
Europe (n = 128)	37 (28.9)	64 (50.0)	27 (21.1)	
Middle East (n = 127)	53 (41.7)	62 (48.8)	12 (9.4)	
Latin America (n = 5)	2 (40.0)	3 (60.0)	0 (0.0)	
Total (n = 260)	92 (35.4)	129 (49.6)	39 (15.0)	0.0467

<sup>a</sup> Pearson's Chi square test for differences in *IL28B* rs12979860 genotype by variables

protective effect of the CC genotype. These data suggest that *IL28B* and TLR-2 are functionally interconnected in HCV disease-specific phenomena.

Baseline factors predictive of cirrhosis/transition to cirrhosis are similar to those reported elsewhere (Nouredin et al. 2013; Falletti et al. 2011; Bochud et al. 2012; Rueger et al. 2015; Wright et al. 2003). It should be noted that attendance at a clinic in Asia (vs Europe) was significantly associated with cirrhosis/transition to cirrhosis in G1 patients, which seems counterintuitive given that the CC genotype was more prevalent in Asian patients. However, this result may be explained by the greater proportion of Asian than European patients with cirrhosis at baseline (~53 vs ~25%).

Overall, the Gen-C study supports previously published frequency distributions of *IL28B* genotypes. The

CC genotype was less common in G1 and G4 than G2 and G3 patients, and the proportions of CC patients in each HCV genotype agreed with previous estimates (De Nicola et al. 2012; Falletti et al. 2011; Bochud et al. 2012; Mottola et al. 2015). The geographic distribution of rs12979860 genotypes also agrees with previous reports, with the highest prevalence of the C allele in Asia, and the highest prevalence of the TT genotype in Latin America (Thomas et al. 2009; Ge et al. 2009). Finally, ethnic associations with s12979860 genotypes agree with previous reports, with the lowest prevalence of the C allele in Black patients, and the highest in Asian patients (Thomas et al. 2009; Ge et al. 2009).

Limitations include the small amount of METAVIR data collected, which tempers conclusions regarding *IL28B* genotype, inflammatory grade and fibrosis stage. Rapid fibrosis progression is associated with factors other than *IL28B* genotype, such as alcohol consumption, liver disease other than CHC, HIV-HCV co-infection and

glucose intolerance, which, notwithstanding our MLR analysis, could have confounded the results.

In summary, an increasing number of rs12979860 T alleles is associated with an increased prevalence of cirrhosis/transition to cirrhosis in treatment-naïve patients with HCV G1 infection. When the G1 population was categorized geographically, this association was evident in the large subgroup of European Caucasians with HCV G1 infection but not in the smaller subgroups of G1-infected patients from Asia, Latin America or the Middle East. Thus, the presence of the T allele may be used to prioritize treatment for G1 patients who are at increased risk of progressing to cirrhosis.

## Additional file

**Additional file 1.** List of investigators, and associations between *IL28B* genotype and liver fibrosis/inflammation in different subgroups and HCV genotypes.

## Abbreviations

ALT: alanine transaminase; AST: aspartate transaminase; APRI: AST to platelet ratio; CHC: chronic hepatitis C; HCV: hepatitis C virus; G: genotype; IFN: interferon; IL28B: interleukin 28B; MLR: multiple logistic regression; SNP: single nucleotide polymorphism; SVR: sustained virological response; TLR: toll-like receptor.

## Authors' contributions

AM, GRF and FT participated in the study concept and design. VdL, FB, JB, JK, JV, and NR were involved in acquisition of data. DM, FT, GB, AM and GRF were involved in analysis and interpretation of data. AM, VdL, FB, JB, JK, JV, NR, DM and GRF were involved in drafting the manuscript. All authors read and approved the final manuscript.

## Author details

<sup>1</sup> Liver Unit, IRCCS Hospital 'Casa Sollievo della Sofferenza', San Giovanni Rotondo 71013, Italy. <sup>2</sup> Hepatology Unit, Hôpital Haut-Lévêque, CHU Bordeaux, 33600 Pessac, France. <sup>3</sup> Hepatology Unit, Groupe Hospitalier Nord, CHU Lyon, 69004 Lyon, France. <sup>4</sup> Gastroenterology Department, University of Chile Clinical Hospital, Santiago 8380456, Chile. <sup>5</sup> Latvian Centre of Infectious Diseases, LLC Riga East University Hospital, Riga 1006, Latvia. <sup>6</sup> Centre of Hepatology, Gastroenterology and Dietetics, Vilnius University, 08661 Vilnius, Lithuania. <sup>7</sup> Center for Infectious Diseases, West Tallinn Central Hospital, 10617 Tallinn, Estonia. <sup>8</sup> Biostatistics, PROMETRIS GmbH, 68219 Mannheim, Germany. <sup>9</sup> Global Medical Affairs, F. Hoffmann-La Roche Ltd, 4074 Basel, Switzerland. <sup>10</sup> Present Address: AbbVie, North Chicago, IL, USA. <sup>11</sup> Global Product Development Medical Affairs, F. Hoffmann-La Roche Ltd, 4074 Basel, Switzerland. <sup>12</sup> Institute of Cellular and Molecular Sciences, Queen Mary University of London, London E1 2AT, UK.

## Acknowledgements

This research was funded by F. Hoffmann-La Roche Ltd, Basel, Switzerland. Support for third-party writing assistance for this manuscript, furnished by Jake Burrell PhD and Blair Jarvis MSc, Health Interactions, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

## Competing interests

AMangia served in advisory committees or review panels for Gilead Sciences, Bristol-Myers Squibb and Achillion, as a speaker for Janssen Cilag and MSD and received research funding from Roche. V De Ledinghen served in advisory committees or review panels for Gilead Sciences, Bristol-Myers Squibb, Janssen Cilag, MSD and AbbVie. F Bailly served in advisory committees or review panels and as a speaker for AbbVie, Bristol-Myers Squibb, Merck, Gilead Sciences and Janssen. J Brahm served in advisory committees or review panels

and as a speaker for Gilead Sciences, Bristol-Myers Squibb, AbbVie and Roche. D Messinger is an employee of PROMETRIS GmbH, the clinical research organization providing data management and statistical services to Roche. F Tatsch was an employee of F. Hoffmann-La Roche at the time of the study. Now an employee of AbbVie. G Bakalos is an employee of F. Hoffmann-La Roche. GR Foster has received speaker and consultancy fees from AbbVie, Bristol-Myers Squibb, Merck, Gilead, Janssen, Tekmira, Alnylam and Roche. J Keiss, J Valantinas and N Rasmann declare that they have no competing interests.

## Ethics committees

The following ethics committees/institutional review boards, listed by country, considered and approved the study protocol.

**Argentina:** Comité de Ética en Investigación, Mar del Plata; Comité de Docencia del Centro Oncológico Integral, Mar del Plata; Comité de Ética DIM Clínica Privada, Ramos Mejía La Matanza; Comité de Docencia e Investigación DIM Clínica Privada, Ramos Mejía La Matanza.

**Belgium:** Ethisch Comité Uz Gent, Universitair Ziekenhuis Gent, Gent.

**Chile:** Comité de Ética Científico Servicio de Salud Metropolitano Norte, Independencia; Comité de Ética Hospital Clínico Universidad de Chile, Independencia; Comité de Ética Científico Servicio de Salud Metropolitano Central, Santiago; Comité de Ética en Investigación Pontificia Universidad Católica de Chile Facultad de Medicina, Santiago.

**Egypt:** Ain Shams University EC, Cairo; Tanta University EC, Tanta-Gharbia; Menoufiya University National Liver Institute IRB, Shibin El Kom; Theodore Institute, Imbaba Giza; Alexandria University EC, Alexandria; Kasr Eini Internal Medecin Department, Gastroenterology and Hepatology unit EC, Cairo.

**Estonia:** Tallinn Medical Research Ethics Committee, Tallinn.

**France:** Comité de Protection des Personnes Sud-Ouest et Outre Mer III, Bordeaux.

**Germany:** Ethik-Kommission der Friedrich-Alexander Universität (FAU) Erlangen-Nürnberg, Erlangen; Ethik-Kommission der Universität zu Lübeck, Lübeck; Ärztekammer Nordrhein, Düsseldorf; Ethik-Kommission an der Medizinischen Fakultät der Eberhard-Karls-Universität und am Universitätsklinikum Tübingen, Tübingen; Med. Ethik-Kommission II, Mannheim; Geschäftsstelle der Ethikkommission - Universität zu Köln, Köln; Landesärztekammer Baden-Württemberg, Stuttgart; Ethik-Kommission bei der Landesärztekammer Hessen, Frankfurt; Ethik-Kommission der Otto-von-Guericke-Universität Magdeburg, Magdeburg; Ethikkommission an der Medizinischen Fakultät der Universität Rostock, Rostock; Ethik-Kommission - Medizinische Fakultät der Universität Duisburg-Essen, Essen; Ethik-Kommission an der Medizinischen Fakultät der RWTH Aachen, Aachen; Ethik-Kommission Würzburg, Würzburg; Ethik-Kommission Universitätsklinikum Frankfurt, Frankfurt.

**Greece:** Hippokratia Hospital Institutional Review Board, Thessaloniki; University Hospital of Alexandroupolis Institutional Review Board, Alexandroupolis; University Hospital of Ioannina Institutional Review Board, Ioannina; University Hospital of Larissa Institutional Review Board, Larissa; Hippokratia Hospital Institutional Review Board, Athens; Agioi Anargiroi Hospital of Kifissia Institutional Review Board, Kifissia; Anticancer Hospital Agios Savvas Institutional Review Board, Athens; University Hospital of Patras Institutional Review Board, Patras.

**Italy:** Comitato Etico Ospedale San Camillo Forlanini, Roma; Comitato Etico Azienda Policlinico Umberto I, Roma; Comitato Etico per la sperimentazione clinica dei medicinali AUSL 8 di Arezzo, Arezzo; Comitato Etico AOU Maggiore della Carità, Novara; Comitato Etico ASL NA 3 Sud, Brusciano; Comitato Etico IRCCS S. De Bellis, Castellana Grotte; Comitato Etico AOU Policlinico P. Giaccone, Palermo; Comitato Etico AO Treviglio AO Papa Giovanni XXIII, Treviglio; Comitato Etico AOU. Cagliari, Cagliari; Comitato Etico ASL TO2, Torino; Comitato Etico AO Bianchi Melacchino Morelli, Calabria; Comitato Etico ASL BT, Andria; Ufficio Ricerche Cliniche Ospedale San Raffaele IRCCS Lombardia, Milano; Comitato Etico IRCCS AOU.San Martino – IST, Genova; Comitato Etico Provinciale di Modena, Modena; Comitato Etico IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo; Comitato Etico AO Ospedale di Circolo Busto Arsizio, Busto Arsizio; Comitato Etico AOU. Policlinico G. Martino, Messina; Comitato Etico Ospedale Luigi Sacco Milano Area A, Milano; Comitato Etico per la Sperimentazione AOU Padova, Padova; Comitato Etico AOU S.Maria della Misericordia – CERU Udine, Udine; Comitato Etico AO San Paolo - Milano Area A, Milano; Comitato Etico Indipendente Policlinico S. Orsola-Malpighi, Bologna; Comitato Etico Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico – Milano Area B, Milano; Comitato Etico ASL NA 1, Napoli; Comitato Etico Scientifico AO Ospedale Niguarda Ca' Granda – Milano Area C, Milano; Comitato Etico ASL 1 Sassari – ASL Sassari, Sassari; Comitato Etico ASL

Caserta, Caserta; Sottocomitato Etico per le sperimentazioni cliniche sull'uomo AUSL 6, Livorno; Comitato Etico ARNAS Garibaldi, Catania; Comitato Etico AO A.Cardarelli, Napoli; Comitato Etico Indipendente AO. Policlinico Consorziabile – CEI, Bari; Comitato Bioetico ARNAS Ospedali Civico Di Cristina Benfratelli, Palermo; Comitato Etico AOU. Careggi – CEAVCE, Firenze; Comitato di Etica ASL Salerno, Nocera Inferiore; Comitato Etico Ospedali FBF S.Giuseppe Milano e Sacra Famiglia Erba – Milano Area B, Milano; Comitato Etico Università Cattolica S. Cuore - Policlinico Gemelli, Roma; Comitato Etico Azienda Ospedaliera Sant'Andrea, Roma; Comitato Etico Provinciale di Reggio Emilia, Reggio Emilia; Comitato Etico AUSL di Piacenza, Piacenza; Comitato Etico Aziendale ASL 2 Savonese – CER S.Martino, Savona; Comitato Etico AOU. San Luigi Gonzaga – CEI S.Luigi Gonzaga, Orbassano; Comitato di Etica Università degli studi G. D'Annunzio e ASL 2 Lanciano-Vasto-Chieti – ASL 1 CH, Chieti Scalo; Comitato Etico Provinciale di Parma – CE per Parma, Parma; Comitato Etico AOU Seconda Università di Napoli, Napoli; Comitato Etico AORN. San Giuseppe Moscati, Avellino; Comitato Etico per la sperimentazione clinica Provincia di Rovigo, Rovigo; Comitato Etico Indipendente AOG Brotzu - AOU Cagliari, Cagliari; CE dell' Azienda Ospedaliero-Universitaria AOU Ospedali Riuniti "Umberto I, Lancisi, Salesi", Ancona; Comitato Etico IRCCS INMI L. Spallanzani, Roma.

**Kuwait:** Joint Committee For The Protection of Human Subjects In Research, Safat.

**Latvia:** Ethics Committee for Clinical Research at Pauls Stradins Clinical University Hospital Development Society, Riga.

**Lebanon:** American University of Beirut IRB, Hamra; Nabatieh Governmental Hospital IEC, Nabatieh; Hotel Dieu De France IEC, Ashrafieh; Haykel Hospital IEC, Tripoli; Sahel General Hospital IEC, Dahieh; Rafic Hariri University Hospital IRB, Beirut; Commission d'Ethique de la Recherche (CER), Baabda.

**Lithuania:** State Medicines Control Agency/Lithuanian Bioethics Committee, Vilnius.

**Macedonia:** Eticka Komisija, Ministerstvo za zdravstvo, Skopje.

**Mexico:** Comité de Investigación para estudios en Humanos, Mexico City; Comisión Nacional de Investigación Científica, Piso.

**Oman:** College of Medicine and Health Sciences, Sultanate of Oman

**Pakistan:** Allied Med Ethics, Shan Hospital, Karachi; Ethics Review Committee, South City Hospital, Karachi; Institutional Review Board, Lahore General Hospital, Post Graduate Medical Institute, Lahore; Institutional Review Board, Shaikh Zayed Hospital, Lahore; Ethics Review Committee, Chaudhry Hospital, Gujranwala; Institutional Review Board/Ethics Committee, Doctors Hospital and Medical Center, Lahore; Secretariat Ethical Review Committee (ERC), Faisalabad.

**Peru:** Comité de Etica del Hospital Rebagliati, Lima; Comité de Etica en Investigacion del Hospital Nacional Guillermo Almenara Irigoyen, Lima;

**Portugal:** Comissão de Ética para a Saúde do Centro Hospitalar do Baixo Vouga, EPE, Aveiro; Comissão de Ética para a Saúde do Hospital Professor Dr. Fernando da Fonseca, EPE, Amadora; Comissão de Ética para a Saúde do Hospital de Faro, EPE, Faro; Comissão de Ética para a Saúde do Centro Hospitalar do Porto, EPE, Porto; Comissão de Ética para a Saúde do Centro Hospitalar de Lisboa Ocidental, EPE, Lisboa; Comissão de Ética para a Saúde do Hospital Garcia de Orta, EPE, Almada; Comissão de Ética para a Saúde do Centro Hospitalar Lisboa Norte, EPE, Lisboa; Comissão de Ética para a Saúde do Hospital de São João, EPE, Porto.

**Qatar:** Medical Research Center at Hamad Medical Corporation, Doha.

**Romania:** Comisia Națională de Bioetică a Medicamentului și a Dispozitivelor Medicale, Bucharest.

**Serbia:** Ethics Committee Clinical Center of Vojvodina, Novi Sad; Ethics Committee Clinical Hospital Center Zvezdara, Belgrade.

**Slovakia:** Eticka Komisia BSK, Bratislava; Eticka Komisia SZU, Bratislava; Eticka Komisia FNŠP JA Reimanna, Presov; Eticka Komisia UNM, Martin; Eticka Komisia un Bratislava Nemocnica Akad. L. Derera, Bratislava; Eticka Komisia FNŠP FDR, Banska Bystrica.

**Sweden:** Regionala Etikprovningssamnden i Uppsala, Uppsala.

**Switzerland:** Comitato Etico Cantonale, Bellinzona; Ethikkommission Kantonsospital, St Gallen.

**Syria:** Ministry of Health Syria, Damascus.

**Taiwan:** China Medical University and Hospital Research Ethics Committee, Taichung City; Chang Gung Medical Foundation Institutional Review Board, Guishan Township, Taoyuan County; National Taiwan University Hospital Research Ethics Committee, Taipei City; Kaohsiung Medical University Chung-Ho Memorial Hospital Institutional Review Board, Kaohsiung City; Institutional Review Board, Taipei Veterans General Hospital, Taipei City

**Turkey:** Ankara Universitesi Tip Fakultesi Klinik Arastirmalar Etik Kurulu, Ankara.

**UAE:** Al Qassimi Clinical Research Center, Sharjah; Medical Research Committee, Dubai Health authority, Dubai.

**Venezuela:** Comité de Etica Hospital Dr. Domingo Luciani, Caracas; Comité de Ética Hospital Clinico Maracaibo, Maracaibo; Comité de Ética para la Investigación Centro Medico Docente La Trinidad, Caracas; Comité de Bioetica Centro Médico La Floresta, Caracas; Comité de Bioetica para la Investigación Hospital de Clinicas Caracas, Caracas.

#### Informed consent in studies with human subjects

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 and in line with the guidelines for good clinical practice set out in the International Conference on Harmonisation (ICH) Tripartite Guideline. All patients included in the study provided written, informed consent.

Received: 15 July 2016 Accepted: 7 November 2016

Published online: 18 November 2016

#### References

- Abe H, Ochi H, Maekawa T, Hayes CN, Tsuge M, Miki D et al (2010) Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. *J Hepatol* 53:439–443
- Asselah T, De Muynck S, Broët P, Masliah-Planchon J, Blanluet M, Bièche I et al (2012) IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. *J Hepatol* 56:527–532
- Bochud PY, Bibert S, Kutalik Z, Patin E, Guernon J, Nalpas B et al (2012) IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. *Hepatology* 55:384–394
- Bonnet D, Guivarch M, Berard E, Combis JM, Remy AJ, Glibert A et al (2014) Telaprevir- and boceprevir-based tritherapies in real practice for F3-F4 pretreated hepatitis C virus patients. *World J Hepatol* 6:660–669
- D'Ambrosio R, Aghemo A, De Francesco R, Rumi MG, Galmozzi E, De Nicola S et al (2014) The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent. *Int J Mol Sci* 15:7213–7224
- De Nicola S, Aghemo A, Rumi MG, Galmozzi E, Valenti L, Soffredini R et al (2012) Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. *Hepatology* 55:336–342
- De Re V, De Zorzi M, Caggiari L, Lauletta G, Tornesello ML, Fognani E et al (2016) HCV-related liver and lymphoproliferative diseases: association with polymorphisms of IL28B and TLR2. *Oncotarget*. doi:10.18632/oncotarget.9303
- Di Marco V, Bronte F, Calvaruso V, Capra M, Borsellino Z, Maggio A et al (2012) IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection. *Haematologica* 97:679–686
- Fabris C, Falletti E, Cussigh A, Bitetto D, Fontanini E, Bignulin S et al (2011) IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC. *J Hepatol* 54:716–722
- Falletti E, Bitetto D, Fabris C, Cussigh A, Fornasiero E, Cmet S et al (2011) Role of interleukin 28B rs12979860 C/T polymorphism on the histological outcome of chronic hepatitis C: relationship with gender and viral genotype. *J Clin Immunol* 31:891–899
- Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ et al (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. *Nature* 461:399–401
- Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P et al (2004) Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. *Ann Intern Med* 140:346–355

- Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS et al (2013) Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. *N Engl J Med* 368:1867–1877
- Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV et al (2014) Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. *Lancet* 384:403–413
- Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC et al (2013) Sofosbuvir for previously untreated chronic hepatitis C infection. *N Engl J Med* 368:1878–1887
- Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K et al (2010) An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. *Gastroenterology* 139:821–827
- Manns M, Marcellin P, Poordad F, de Araujo ES, Buti M, Horsmans Y et al (2014) Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet* 384:414–426
- Marabita F, Aghemo A, De Nicola S, Rumi MG, Cheroni C, Scavelli R et al (2011) Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. *Hepatology* 54:1127–1134
- Mottola L, Cenderello G, Piazzolla VA, Forte P, Carretta V, Mecenate F et al (2015) Interleukin-28B genetic variants in untreated Italian HCV-infected patients: a multicentre study. *Liver Int* 35:482–488
- Muir AJ, Bornstein JD, Killen PG (2004) Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. *N Engl J Med* 350:2265–2271
- Noureddin M, Wright EC, Alter HJ, Clark S, Thomas E, Chen R et al (2013) Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. *Hepatology* 58:1548–1557
- Pawlotsky JM (2014) New hepatitis C therapies: the toolbox, strategies, and challenges. *Gastroenterology* 146:1176–1192
- Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS et al (2012) Factors that predict response of patients with hepatitis C virus infection to boceprevir. *Gastroenterology* 143:608–618
- Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T et al (2010) Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. *Gastroenterology* 138:1338–1345
- Rembeck K, Alsiö A, Christensen PB, Färkkilä M, Langeland N, Buhl MR et al (2012) Impact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3. *PLoS ONE* 7:e29370
- Rodriguez-Torres M, Jeffers LJ, Sheikh MY, Rossaro L, Ankoma-Sey V, Hamzeh FM et al (2009) Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. *N Engl J Med* 360:257–267
- Rueger S, Bochud PY, Dufour JF, Mullhaupt B, Semela D, Heim MH et al (2015) Impact of common risk factors of fibrosis progression in chronic hepatitis C. *Gut* 64:1605–1615
- Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML et al (2009) IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. *Nat Genet* 41:1100–1104
- Susser S, Herrmann E, Lange C, Hamdi N, Muller T, Berg T et al (2014) Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C. *PLoS ONE* 9:e112592
- Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N et al (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. *Nat Genet* 41:1105–1109
- Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huiginn C et al (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. *Nature* 461:798–801
- Thomas E, Gonzalez VD, Li Q, Modi AA, Chen W, Noureddin M et al (2012) HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. *Gastroenterology* 142:978–988
- Watanabe T, Sugauchi F, Tanaka Y, Matsuura K, Yatsushashi H, Murakami S et al (2013) Hepatitis C virus kinetics by administration of pegylated interferon-alpha in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene. *Gut* 62:1340–1346
- Wright M, Goldin R, Fabre A, Lloyd J, Thomas H, Trepo C et al (2003) Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study. *Gut* 52:574–579
- Yu ML, Dai CY, Huang JF, Chiu CF, Yang YH, Hou NJ et al (2008) Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. *Hepatology* 47:1884–1893
- Zhang Y, Zhu SL, Chen J, Li LQ (2016) Meta-analysis of associations of interleukin-28B polymorphisms rs8099917 and rs12979860 with development of hepatitis virus-related hepatocellular carcinoma. *Oncol Ther* 9:3249–3257

Submit your manuscript to a SpringerOpen® journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Immediate publication on acceptance
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ► [springeropen.com](http://springeropen.com)